Every 11 minutes, an American dies by suicide. Millions more struggle to manage their mental health, cycling through medications, therapy appointments, and hospital visits without ever finding relief. 

In late April, the FDA took a decisive step toward addressing this prolonged health emergency. In response to President Donald Trump’s recent executive order, the agency announced plans to expedite the review of certain psychedelic medicines for serious mental health conditions.